TITUSVILLE, N.J., Oct. 29 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular injection, for the treatment of schizophrenia and the prevention of recurrence of the symptoms of schizophrenia.
Paliperidone palmitate is a long-acting injectable ester of the active ingredient in INVEGA(TM)(1) which utilizes Elan's NanoCrystal(R) Technology. Upon approval, paliperidone palmitate will be marketed in the U.S. by Janssen, L.P.
Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness. In the United States, there are currently 2,000,000 people with schizophrenia, with men and women affected equally. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well as by disorganized thinking.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is headquartered in Raritan, New Jersey (USA), and has nine sites throughout Europe and the United States. J&JPRD employs approximately 3,500 people and is leveraging drug discovery, drug evaluation, and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health.
Janssen, L.P., based in Titusville, N.J., is a subsidiary of Johnson &
Johnson, and is the only pharmaceutical company in the U.S. dedicated
solely to mental health. The company currently markets prescription
medications for the treatment of schizophrenia, bipolar mania, and
irritability associated with autistic disorder. F
|SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.|
Copyright©2007 PR Newswire.
All rights reserved